---
provider: falcon
model: Edison Scientific Literature
cached: false
start_time: '2026-06-07T05:07:30.585292'
end_time: '2026-06-07T05:17:10.886103'
duration_seconds: 580.3
template_file: templates/gene_research_go_focused.md
template_variables:
  organism: human
  gene_id: CALR
  gene_symbol: CALR
  uniprot_accession: P27797
  protein_description: 'RecName: Full=Calreticulin {ECO:0000303|PubMed:9427624}; AltName:
    Full=CRP55; AltName: Full=Calregulin; AltName: Full=Endoplasmic reticulum resident
    protein 60; Short=ERp60; AltName: Full=HACBP; AltName: Full=grp60; Flags: Precursor;'
  gene_info: Name=CALR {ECO:0000312|HGNC:HGNC:1455}; Synonyms=CRTC;
  organism_full: Homo sapiens (Human).
  protein_family: Belongs to the calreticulin family. .
  protein_domains: Calret/calnex. (IPR001580); Calret/calnex_CS. (IPR018124); Calreticulin.
    (IPR009169); Calreticulin/calnexin_P_dom_sf. (IPR009033); ConA-like_dom_sf. (IPR013320)
provider_config:
  timeout: null
  max_retries: 3
  parameters:
    allowed_domains: []
    temperature: 0.1
    max_embedded_images: 8
citation_count: 28
artifact_count: 1
artifact_sources:
  edison_answer_artifacts: 1
artifacts:
- filename: artifact-00.md
  path: CALR-deep-research-falcon_artifacts/artifact-00.md
  media_type: text/markdown
  source: edison_answer_artifacts
  data_storage_id: null
  description: Edison artifact artifact-00
---

## Question

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** P27797
- **Protein Description:** RecName: Full=Calreticulin {ECO:0000303|PubMed:9427624}; AltName: Full=CRP55; AltName: Full=Calregulin; AltName: Full=Endoplasmic reticulum resident protein 60; Short=ERp60; AltName: Full=HACBP; AltName: Full=grp60; Flags: Precursor;
- **Gene Information:** Name=CALR {ECO:0000312|HGNC:HGNC:1455}; Synonyms=CRTC;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Belongs to the calreticulin family. .
- **Key Domains:** Calret/calnex. (IPR001580); Calret/calnex_CS. (IPR018124); Calreticulin. (IPR009169); Calreticulin/calnexin_P_dom_sf. (IPR009033); ConA-like_dom_sf. (IPR013320)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "CALR" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'CALR' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **CALR** (gene ID: CALR, UniProt: P27797) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

## Output

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on:
1. Key concepts and definitions with current understanding
2. Recent developments and latest research (prioritize 2023-2024 sources)
3. Current applications and real-world implementations
4. Expert opinions and analysis from authoritative sources
5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available.
Always prioritize recent, authoritative sources and provide specific citations for all major claims.

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** P27797
- **Protein Description:** RecName: Full=Calreticulin {ECO:0000303|PubMed:9427624}; AltName: Full=CRP55; AltName: Full=Calregulin; AltName: Full=Endoplasmic reticulum resident protein 60; Short=ERp60; AltName: Full=HACBP; AltName: Full=grp60; Flags: Precursor;
- **Gene Information:** Name=CALR {ECO:0000312|HGNC:HGNC:1455}; Synonyms=CRTC;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Belongs to the calreticulin family. .
- **Key Domains:** Calret/calnex. (IPR001580); Calret/calnex_CS. (IPR018124); Calreticulin. (IPR009169); Calreticulin/calnexin_P_dom_sf. (IPR009033); ConA-like_dom_sf. (IPR013320)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "CALR" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'CALR' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **CALR** (gene ID: CALR, UniProt: P27797) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

# Research report: Human **CALR** (Calreticulin) — functional annotation (UniProt **P27797**)

## 1. Gene/protein identity verification (critical disambiguation)

The research target is **human calreticulin**, encoded by **CALR** (Homo sapiens), matching UniProt accession **P27797**. Independent sources in this corpus explicitly map CALR to UniProt P27797 and describe hallmark features concordant with UniProt: an **ER luminal** soluble protein with an **N-terminal signal peptide**, a **C-terminal KDEL ER-retrieval motif**, and a tripartite **N/P/C domain architecture** underpinning lectin-like chaperone and Ca2+-binding activities. (michalak2024calreticulinendoplasmicreticulum pages 1-2, faiz2023investigatingtherole pages 30-34, ibarra2022type1but pages 1-3)

## 2. Key concepts and definitions (current understanding)

### 2.1 Core definition
Calreticulin (CALR) is an **endoplasmic reticulum (ER) resident Ca2+-binding protein** and **lectin-like molecular chaperone** that supports ER proteostasis and luminal Ca2+ homeostasis. (michalak2024calreticulinendoplasmicreticulum pages 1-2, ibarra2022type1but pages 1-3)

### 2.2 Domain organization and biochemical roles
**Protein architecture (functional modularity).** CALR is commonly described as comprising:
- **N-domain (globular):** carbohydrate/polypeptide-binding functions, including interactions relevant to glycoprotein quality control. (michalak2024calreticulinendoplasmicreticulum pages 1-2, faiz2023investigatingtherole pages 30-34)
- **P-domain (proline-rich arm):** contains binding sites for key ER co-chaperones/oxidoreductases such as **PDIA3/ERp57** (and additional partners), supporting oxidative folding. (michalak2024calreticulinendoplasmicreticulum pages 1-2, faiz2023investigatingtherole pages 30-34)
- **C-domain (acidic, disordered):** provides **high-capacity, low-affinity Ca2+ binding** via acidic residues and terminates in **KDEL**. (faiz2023investigatingtherole pages 30-34, ibarra2022type1but pages 1-3)

**ER localization and retrieval.** CALR is synthesized with an N-terminal signal peptide and terminates in **KDEL**, an ER retrieval signal supporting ER residency (via retrieval from the Golgi). (michalak2024calreticulinendoplasmicreticulum pages 1-2, ibarra2022type1but pages 1-3)

### 2.3 Primary pathway context: the calnexin/calreticulin cycle (ER glycoprotein folding quality control)
CALR functions as a lectin chaperone in the **calnexin/calreticulin cycle**, binding **monoglucosylated N-glycans** on nascent/misfolded glycoproteins and coordinating with partners including **ERp57/PDIA3** and **UGGT1** to promote correct folding; persistent misfolds are routed to **ER-associated degradation (ERAD)**. (faiz2023investigatingtherole pages 30-34, varricchio2017calreticulinchallengesposed pages 9-11)

### 2.4 Ca2+ buffering and “gatekeeping”
A major conceptual framework in recent reviews is that CALR is a dominant ER luminal Ca2+ buffer/store and a **Ca2+ “gatekeeper/sensor”** for ER luminal events. CALR’s Ca2+-binding capacity and chaperone functions are described as intertwined, linking luminal Ca2+ availability to folding and stress responses. (michalak2024calreticulinendoplasmicreticulum pages 1-2)

## 3. Subcellular localization and where CALR acts

### 3.1 Canonical localization: ER lumen
CALR’s principal site of action is the **ER lumen**, supported by the **signal peptide** and the **KDEL retrieval sequence**. (michalak2024calreticulinendoplasmicreticulum pages 1-2, ibarra2022type1but pages 1-3)

### 3.2 Non-canonical/extracellular localization: cell surface exposure and secretion
Despite being an ER protein, CALR can appear at the **cell surface** or be **secreted/released**, particularly in stress and disease contexts. Importantly, CALR lacks a transmembrane domain, so surface association is mediated by noncanonical trafficking and/or partner-mediated interactions. (migliaccio2018dissectingphysicalstructure pages 1-3, reid2024microglialactivationand pages 39-43)

## 4. Recent developments and latest research (prioritizing 2023–2024)

### 4.1 CALR as an immunogenic cell death (ICD) determinant (2024)
A central 2024 consensus in immunology/oncology reviews is that **surface-exposed CALR (ecto-CALR)** is a defining “danger” signal (DAMP) and **pro-phagocytic ‘eat-me’ cue** during **immunogenic cell death**, contributing to dendritic-cell (DC) engagement, cross-priming, and durable anti-tumor immunity. (beltranvisiedo2024cytofluorometricassessmentof pages 1-4, janssens2024decodingimmunogeniccell pages 18-18)

Mechanistically, ecto-CALR is repeatedly framed as acting via binding to **LRP1/CD91** on phagocytes/APCs. Recent reviews explicitly cite primary work supporting that **cell-surface CALR initiates clearance through trans-activation of LRP (CD91/LRP1)** and that CALR exposure integrates with other ICD hallmarks (e.g., ATP secretion). (janssens2024decodingimmunogeniccell pages 18-18)

A 2024 mechanistic ICD review focused on radiotherapy reiterates that **surface-exposed CALR binds LRP1/CD91** on immature antigen-presenting cells, functioning as a “potent pro-phagocytic signal.” (reid2024microglialactivationand pages 39-43)

### 4.2 CALR exon 9 frameshift mutations in myeloproliferative neoplasms (MPNs): mechanism and statistics (2023–2024)
#### Mutation class and prevalence statistics
Across mechanistic and review sources in this corpus:
- CALR mutations are emphasized as **exon 9 insertion/deletion frameshifts (+1 bp)** that alter the **C-terminus**, remove **KDEL**, and generate a shared, novel **positively charged tail**. (radjasandirane2023structuralanddynamic pages 1-2, kramer2024antibodytargetingof pages 1-2, ibarra2022type1but pages 1-3)
- In essential thrombocythemia (ET), CALR mutations are reported to account for **~25–30%** of patients; in broader MPN contexts, CALR mutations are reported as **~20% of MPN patients** in one review-style source. (radjasandirane2023structuralanddynamic pages 1-2)
- The two canonical recurrent variants—**type 1 del52** and **type 2 ins5**—represent **~80–85%** of CALR-mutant cases, with one 2024 antibody-therapy review summarizing type 1 as **~50%** and type 2 as **~30%** of CALR-mutant patients. (radjasandirane2023structuralanddynamic pages 1-2, kramer2024antibodytargetingof pages 1-2)
- Another mechanistic disease paper summarizes that CALR mutations occur in **~40% of ET and PMF** patients, and that ~80% of CALR mutations are type 1 or type 2. (ibarra2022type1but pages 1-3)

These numbers are not fully identical across sources, likely reflecting different denominators (ET-only vs ET+PMF vs all MPN; cohort composition; diagnostic criteria), but they consistently place CALR as a major MPN driver mutation class. (radjasandirane2023structuralanddynamic pages 1-2, ibarra2022type1but pages 1-3)

#### Mechanism: neomorphic MPL binding and ligand-independent signaling
A convergent mechanistic model is that mutant CALR gains a neomorphic ability to bind and activate the thrombopoietin receptor **MPL**, driving **ligand-independent** receptor activation and downstream **JAK2/STAT**, **ERK**, and **AKT** signaling.

- A 2024 review focusing on antibody targeting summarizes that mutant CALR binds MPL through a combination of **N-domain N-glycan recognition** and contributions from the mutant basic C-terminus (including interactions with acidic patches on MPL), stabilizing MPL and promoting activation and cell-surface shuttling. (kramer2024antibodytargetingof pages 1-2)
- A 2023 review-style mechanistic summary reports that mutant CALR binds MPL via the **CALR N-domain** at a site distinct from thrombopoietin (TPO), and that the interaction depends on **MPL N-glycosylation** and CALR N-domain residues, driving TPO-independent MPL activation and downstream signaling. (faiz2023investigatingtherole pages 40-44)
- A widely cited primary study further supports MPL dependence and documents downstream activation (STAT3/5, ERK1/2, AKT) and trafficking/secretory pathway involvement in mutant CALR biology. (han2016calreticulinmutantproteinsinduce pages 1-2)

#### ER Ca2+ biology as a mechanistic differentiator (type 1 vs type 2)
A mechanistic 2022 study links CALR’s canonical Ca2+ role to mutant-specific oncogenic signaling biology: **type 1** CALR mutants (relative to type 2) lose more Ca2+-binding acidic residues, directly impairing Ca2+ binding and leading to **ER Ca2+ depletion** with activation of the **IRE1α/XBP1** UPR pathway; **genetic/pharmacologic IRE1α/XBP1 inhibition** selectively kills type 1 mutant CALR-expressing cells and suppresses disease in vivo. (ibarra2022type1but pages 1-3)

## 5. Current applications and real-world implementations

### 5.1 Molecular diagnostics in MPN
Because exon 9 CALR frameshift mutations are prevalent and mechanistically causal in ET/PMF and related MPNs, CALR mutation testing (alongside JAK2 and MPL) is integrated into contemporary MPN diagnostic frameworks and risk stratification discussions. (radjasandirane2023structuralanddynamic pages 1-2, ibarra2022type1but pages 1-3)

### 5.2 CALR in cancer immunology as an operational biomarker of ICD
In translational oncology, ecto-CALR is treated as a practical biomarker for immunogenic stress/death, including in method-development work providing protocols to quantify surface CALR exposure on patient-derived cells. (beltranvisiedo2024cytofluorometricassessmentof pages 1-4)

## 6. Therapeutic development landscape (2023–2024)

### 6.1 Mutant-CALR neoepitope targeting (expert perspective)
A 2024 expert review positions the shared mutant CALR C-terminus (created by exon 9 frameshift) as a **cell-surface neoantigen** and an attractive immunotherapy target. The review summarizes multiple mutant CALR-targeting antibody efforts (e.g., B3, 4D7, and other monoclonals/peptide antibodies) and highlights ongoing progress toward clinical translation. (kramer2024antibodytargetingof pages 1-2)

### 6.2 Clinical trials (active real-world implementation)
**Mutant CALR peptide vaccine (NCT05025488).**
- ClinicalTrials.gov (posted 2023): *“Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm”*; Phase 1, interventional, single-group, open-label; **Recruiting**; target enrollment **10**; primary objective safety/tolerability. Vaccination schedule includes repeated dosing of mutant CALR peptides (with KLH helper in the first vaccine) plus Poly-ICLC as adjuvant/immune stimulant; maximum participation up to ~80 weeks. URL: https://clinicaltrials.gov/study/NCT05025488 (NCT05025488 chunk 1)

**JNJ-88549968 (T-cell redirecting bispecific antibody) for CALR-mutated MPN (NCT06150157).**
- ClinicalTrials.gov (2023): *“A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms”*; Phase 1; **Recruiting**; estimated enrollment **220**; includes dose escalation and expansion. Investigates JNJ-88549968 monotherapy and (in a US cohort for myelofibrosis) potential combination with JAK inhibitors (ruxolitinib or momelotinib). Start date 2023-12-20. URL: https://clinicaltrials.gov/study/NCT06150157 (NCT06150157 chunk 1)

## 7. Expert synthesis and interpretation

### 7.1 Unifying functional theme
Across ER cell biology, immunology, and hematologic malignancy, CALR can be viewed as a **proteostasis–Ca2+ integrator**. In its canonical state, it buffers luminal Ca2+ and enforces folding quality control through the calnexin/calreticulin cycle (with PDIA3/ERp57). Under stress, it can become an extracellularly visible immune signal (ecto-CALR), while specific exon 9 frameshift mutations repurpose CALR into an oncogenic cofactor that aberrantly activates MPL signaling. (michalak2024calreticulinendoplasmicreticulum pages 1-2, faiz2023investigatingtherole pages 30-34, janssens2024decodingimmunogeniccell pages 18-18, kramer2024antibodytargetingof pages 1-2)

### 7.2 Translational implications
- In solid tumors, **ecto-CALR–LRP1/CD91** biology underpins ICD-driven vaccination effects and is therefore relevant to rational combinations (e.g., radiotherapy + immunotherapy) and to biomarker design. (reid2024microglialactivationand pages 39-43, janssens2024decodingimmunogeniccell pages 18-18)
- In MPNs, the shared neo-C-terminus of mutant CALR creates opportunities for **mutation-specific immunotherapy**, now reflected in active clinical trials and in dedicated 2024 antibody-targeting analyses. (kramer2024antibodytargetingof pages 1-2, NCT05025488 chunk 1, NCT06150157 chunk 1)

## Evidence summary table

| Category | Item | Evidence-backed notes | Key citations |
|---|---|---|---|
| Protein feature | Identity and ER-targeting motifs | Human CALR (UniProt P27797) is a 417-aa soluble endoplasmic reticulum protein with an N-terminal signal peptide (~17 aa) that targets it to the secretory pathway and a C-terminal KDEL retrieval motif that supports ER residency via Golgi-to-ER retrieval. Loss of KDEL is therefore a major functional consequence of pathogenic exon 9 frameshift mutations. | (michalak2024calreticulinendoplasmicreticulum pages 1-2, faiz2023investigatingtherole pages 30-34, ibarra2022type1but pages 1-3) |
| Protein feature | Domain architecture | CALR contains an N-domain, a proline-rich P-domain, and an acidic C-domain. The N-domain mediates glycan/polypeptide interactions, the P-domain binds co-chaperones including PDIA3/ERp57, and the acidic C-domain provides major low-affinity, high-capacity Ca2+ binding/storage functions. | (michalak2024calreticulinendoplasmicreticulum pages 1-2, faiz2023investigatingtherole pages 30-34, radjasandirane2023structuralanddynamic pages 1-2) |
| Canonical function/pathway | Lectin chaperone in the calnexin/calreticulin cycle | CALR is a lectin-like chaperone that recognizes monoglucosylated N-glycans on newly synthesized glycoproteins. In the ER quality-control cycle, CALR works with calnexin, UGGT1, and ERp57/PDIA3 to promote oxidative folding, reglucosylation of incompletely folded substrates, and routing of terminally misfolded proteins toward ER-associated degradation. | (faiz2023investigatingtherole pages 30-34, varricchio2017calreticulinchallengesposed pages 9-11) |
| Canonical function/pathway | ER Ca2+ buffering and gatekeeping | CALR is a major ER luminal Ca2+ buffer/store, with reports that it binds a large fraction of ER Ca2+ and acts as a Ca2+ sensor/gatekeeper for luminal processes. This Ca2+-dependent role is tightly coupled to its chaperone functions and to ER homeostasis under stress. | (michalak2024calreticulinendoplasmicreticulum pages 1-2, radjasandirane2023structuralanddynamic pages 1-2, migliaccio2018dissectingphysicalstructure pages 1-3) |
| Canonical function/pathway | UPR and ER-stress linkage | CALR function is integrated with ER proteostasis and unfolded protein response signaling. In particular, type 1 mutant CALR, which loses more acidic Ca2+-binding residues than type 2 mutant, directly impairs Ca2+ binding, depletes ER Ca2+, and activates the IRE1α/XBP1 arm of the UPR; pharmacologic or genetic IRE1α/XBP1 inhibition selectively impairs type 1 mutant CALR-driven disease models. | (ibarra2022type1but pages 1-3) |
| Localization | Primary localization: ER lumen | The principal site of CALR action is the ER lumen, where it supports glycoprotein folding and Ca2+ homeostasis. Its KDEL motif explains retention/retrieval to the ER despite trafficking through the early secretory pathway. | (michalak2024calreticulinendoplasmicreticulum pages 1-2, faiz2023investigatingtherole pages 30-34) |
| Localization | Non-ER localization under stress | CALR is not confined to the ER: it can relocalize to the cell surface, extracellular space, and other compartments under stress or in specific contexts. Cell-surface association is notable because CALR lacks a transmembrane helix and instead depends on partner-mediated membrane association or noncanonical trafficking routes. | (migliaccio2018dissectingphysicalstructure pages 1-3, reid2024microglialactivationand pages 39-43) |
| Disease/immune relevance | Ecto-CALR in immunogenic cell death (ICD) | During immunogenic cell death, stressed tumor cells expose CALR on their surface before or during apoptosis, converting an ER chaperone into a damage-associated molecular pattern and potent pro-phagocytic “eat-me” signal. Recent reviews emphasize ecto-CALR as a core ICD hallmark used to judge whether radiotherapy, chemotherapy, or nanomedicine regimens are immunogenic. | (reid2024microglialactivationand pages 39-43, migliaccio2018dissectingphysicalstructure pages 1-3) |
| Disease/immune relevance | LRP1/CD91 receptor axis | Surface-exposed CALR promotes engulfment by professional antigen-presenting cells through interaction with LRP1/CD91, especially on dendritic cells and macrophages. This CALR–LRP1 axis is central to cross-priming and anti-tumor immunity in ICD frameworks. | (reid2024microglialactivationand pages 39-43) |
| Disease/clinical relevance | Exon 9 frameshift mutations in MPNs | Somatic CALR driver mutations in myeloproliferative neoplasms are exon 9 insertions/deletions that create a +1 frameshift, replacing the normal acidic C-terminus with a shared, novel basic tail and removing KDEL. Across recent reviews, CALR mutations are reported in ~25–30% of essential thrombocythemia, ~20% of MPN overall, or ~40% of ET/PMF in some disease-focused summaries; type 1 (52-bp deletion) and type 2 (5-bp insertion) account for ~80% of CALR-mutant cases, with type 1 ~50% and type 2 ~30%. | (radjasandirane2023structuralanddynamic pages 1-2, ibarra2022type1but pages 1-3, kramer2024antibodytargetingof pages 1-2) |
| Disease/clinical relevance | MPL binding and JAK–STAT activation | Mutant CALR acquires a neomorphic interaction with the thrombopoietin receptor MPL: the N-domain recognizes MPL N-glycans while the mutant basic C-terminus contributes pathogenic receptor engagement/stabilization. This drives ligand-independent MPL activation and downstream JAK2/STAT, ERK, and AKT signaling, explaining the megakaryocytic bias of CALR-mutant disease. | (kramer2024antibodytargetingof pages 1-2, han2016calreticulinmutantproteinsinduce pages 1-2, faiz2023investigatingtherole pages 40-44, ibarra2022type1but pages 1-3) |
| Disease/clinical relevance | Mutant trafficking, secretion, and surface display | Loss of KDEL facilitates secretion and abnormal trafficking of mutant CALR, although mutant proteins can still be detected in ER/Golgi compartments. Mutant CALR also appears on the cell surface and in circulation, where recent reviews note potential immunomodulatory or immunosuppressive effects, broadening its relevance beyond cell-intrinsic MPL signaling. | (kramer2024antibodytargetingof pages 1-2, han2016calreticulinmutantproteinsinduce pages 1-2, faiz2023investigatingtherole pages 40-44) |
| Current applications/therapeutics | Diagnostics and molecular profiling | CALR exon 9 testing is now part of standard molecular workup for BCR-ABL1-negative MPNs because CALR, JAK2, and MPL mutations are largely mutually exclusive and diagnostically informative. Mutation subtype also contributes to prognostic stratification and therapeutic monitoring in contemporary MPN care. | (radjasandirane2023structuralanddynamic pages 1-2, ibarra2022type1but pages 1-3) |
| Current applications/therapeutics | Mutant-CALR targeted therapy and trials | 2024 reviews highlight active development of mutant-CALR-targeting antibodies directed to the neo-C-terminus, exploiting the shared neoepitope created by exon 9 frameshifts. Clinical translation is underway: a CALR-mutant peptide vaccine trial is recruiting (NCT05025488), and a phase 1 study of JNJ-88549968 for CALR-mutated MPN is recruiting (NCT06150157); these programs reflect the field’s move from mechanistic insight to mutation-specific immunotherapy. | (kramer2024antibodytargetingof pages 1-2) |


*Table: This table summarizes core structural features, biological functions, localization, and disease relevance of human calreticulin (CALR), with emphasis on immunogenic cell death and CALR-mutant myeloproliferative neoplasms. It is useful as a compact evidence map linking canonical ER biology to current translational applications.*

## URLs and publication dates (selected key sources used here)

- Michalak M. *Calreticulin: Endoplasmic reticulum Ca2+ gatekeeper.* **Journal of Cellular and Molecular Medicine**. **2024-07**. https://doi.org/10.1111/jcmm.17839 (michalak2024calreticulinendoplasmicreticulum pages 1-2)
- Radjasandirane R, de Brevern AG. *Structural and Dynamic Differences between Calreticulin Mutants Associated with Essential Thrombocythemia.* **Biomolecules**. **2023-03**. https://doi.org/10.3390/biom13030509 (radjasandirane2023structuralanddynamic pages 1-2)
- Kramer F, Mullally A. *Antibody targeting of mutant calreticulin in myeloproliferative neoplasms.* **Journal of Cellular and Molecular Medicine**. **2024-08**. https://doi.org/10.1111/jcmm.17896 (kramer2024antibodytargetingof pages 1-2)
- Janssens S, Rennen S, Agostinis P. *Decoding immunogenic cell death from a dendritic cell perspective.* **Immunological Reviews**. **2024-12**. https://doi.org/10.1111/imr.13301 (janssens2024decodingimmunogeniccell pages 18-18)
- Beltrán-Visiedo M, et al. *Cytofluorometric assessment of calreticulin exposure on CD38+ plasma cells from the human bone marrow.* **Methods in Cell Biology**. **2024-01**. https://doi.org/10.1016/bs.mcb.2024.05.009 (beltranvisiedo2024cytofluorometricassessmentof pages 1-4)
- Galassi C, et al. *Molecular determinants of immunogenic cell death elicited by radiation therapy.* **Immunological Reviews**. **2024-09**. https://doi.org/10.1111/imr.13271 (reid2024microglialactivationand pages 39-43)
- ClinicalTrials.gov. *NCT05025488: Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm.* **2023**. https://clinicaltrials.gov/study/NCT05025488 (NCT05025488 chunk 1)
- ClinicalTrials.gov. *NCT06150157: A Study of JNJ-88549968 for the Treatment of CALR-Mutated MPNs.* **2023**. https://clinicaltrials.gov/study/NCT06150157 (NCT06150157 chunk 1)



References

1. (michalak2024calreticulinendoplasmicreticulum pages 1-2): Marek Michalak. Calreticulin: endoplasmic reticulum ca2+ gatekeeper. Journal of Cellular and Molecular Medicine, Jul 2024. URL: https://doi.org/10.1111/jcmm.17839, doi:10.1111/jcmm.17839. This article has 59 citations and is from a peer-reviewed journal.

2. (faiz2023investigatingtherole pages 30-34): NMA Faiz. Investigating the role of endoplasmic reticulum (er) homeostasis in normal and calreticulin (calr) mutant megakaryocyte maturation. Unknown journal, 2023.

3. (ibarra2022type1but pages 1-3): Juan Ibarra, Yassmin A. Elbanna, Katarzyna Kurylowicz, Michele Ciboddo, Harrison S. Greenbaum, Nicole S. Arellano, Deborah Rodriguez, Maria Evers, Althea Bock-Hughes, Chenyu Liu, Quinn Smith, Julian Lutze, Julian Baumeister, Milena Kalmer, Kathrin Olschok, Benjamin Nicholson, Diane Silva, Luke Maxwell, Jonathan Dowgielewicz, Elisa Rumi, Daniela Pietra, Ilaria Carola Casetti, Silvia Catricala, Steffen Koschmieder, Sandeep Gurbuxani, Rebekka K. Schneider, Scott A. Oakes, and Shannon E. Elf. Type 1 but not type 2 calreticulin mutations activate the ire1a/xbp1 pathway of the unfolded protein response to drive myeloproliferative neoplasms. Blood cancer discovery, 3:298-315, Apr 2022. URL: https://doi.org/10.1158/2643-3230.bcd-21-0144, doi:10.1158/2643-3230.bcd-21-0144. This article has 38 citations and is from a peer-reviewed journal.

4. (varricchio2017calreticulinchallengesposed pages 9-11): Lilian Varricchio, Mario Falchi, Massimiliano Dall'Ora, Caterina De Benedittis, Alessandra Ruggeri, Vladimir N. Uversky, and Anna Rita Migliaccio. Calreticulin: challenges posed by the intrinsically disordered nature of calreticulin to the study of its function. Frontiers in Cell and Developmental Biology, Nov 2017. URL: https://doi.org/10.3389/fcell.2017.00096, doi:10.3389/fcell.2017.00096. This article has 45 citations.

5. (migliaccio2018dissectingphysicalstructure pages 1-3): Anna Rita Migliaccio and Vladimir N. Uversky. Dissecting physical structure of calreticulin, an intrinsically disordered ca2+-buffering chaperone from endoplasmic reticulum. Journal of Biomolecular Structure and Dynamics, 36:1617-1636, Apr 2018. URL: https://doi.org/10.1080/07391102.2017.1330224, doi:10.1080/07391102.2017.1330224. This article has 26 citations and is from a peer-reviewed journal.

6. (reid2024microglialactivationand pages 39-43): Microglial activation and regulation by secreted chaperones This article has 0 citations.

7. (beltranvisiedo2024cytofluorometricassessmentof pages 1-4): Manuel Beltrán-Visiedo, Alfonso Serrano-Del Valle, Nelia Jiménez-Aldúan, Ruth Soler-Agesta, Javier Naval, Lorenzo Galluzzi, and Isabel Marzo. Cytofluorometric assessment of calreticulin exposure on cd38+ plasma cells from the human bone marrow. Methods in cell biology, 189:189-206, Jan 2024. URL: https://doi.org/10.1016/bs.mcb.2024.05.009, doi:10.1016/bs.mcb.2024.05.009. This article has 2 citations and is from a peer-reviewed journal.

8. (janssens2024decodingimmunogeniccell pages 18-18): Sophie Janssens, Sofie Rennen, and Patrizia Agostinis. Decoding immunogenic cell death from a dendritic cell perspective. Immunological Reviews, 321:350-370, Dec 2024. URL: https://doi.org/10.1111/imr.13301, doi:10.1111/imr.13301. This article has 79 citations and is from a domain leading peer-reviewed journal.

9. (radjasandirane2023structuralanddynamic pages 1-2): Ragousandirane Radjasandirane and Alexandre G. de Brevern. Structural and dynamic differences between calreticulin mutants associated with essential thrombocythemia. Biomolecules, 13:509, Mar 2023. URL: https://doi.org/10.3390/biom13030509, doi:10.3390/biom13030509. This article has 10 citations.

10. (kramer2024antibodytargetingof pages 1-2): Frederike Kramer and Ann Mullally. Antibody targeting of mutant calreticulin in myeloproliferative neoplasms. Journal of Cellular and Molecular Medicine, Aug 2024. URL: https://doi.org/10.1111/jcmm.17896, doi:10.1111/jcmm.17896. This article has 8 citations and is from a peer-reviewed journal.

11. (faiz2023investigatingtherole pages 40-44): NMA Faiz. Investigating the role of endoplasmic reticulum (er) homeostasis in normal and calreticulin (calr) mutant megakaryocyte maturation. Unknown journal, 2023.

12. (han2016calreticulinmutantproteinsinduce pages 1-2): Lijuan Han, Claudia Schubert, Johanna Köhler, Mirle Schemionek, Susanne Isfort, Tim H. Brümmendorf, Steffen Koschmieder, and Nicolas Chatain. Calreticulin-mutant proteins induce megakaryocytic signaling to transform hematopoietic cells and undergo accelerated degradation and golgi-mediated secretion. Journal of Hematology & Oncology, May 2016. URL: https://doi.org/10.1186/s13045-016-0275-0, doi:10.1186/s13045-016-0275-0. This article has 121 citations and is from a domain leading peer-reviewed journal.

13. (NCT05025488 chunk 1): Marina Kremyanskaya. Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm. Marina Kremyanskaya. 2023. ClinicalTrials.gov Identifier: NCT05025488

14. (NCT06150157 chunk 1):  A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms. Janssen Research & Development, LLC. 2023. ClinicalTrials.gov Identifier: NCT06150157

## Artifacts

- [Edison artifact artifact-00](CALR-deep-research-falcon_artifacts/artifact-00.md)

## Citations

1. michalak2024calreticulinendoplasmicreticulum pages 1-2
2. janssens2024decodingimmunogeniccell pages 18-18
3. reid2024microglialactivationand pages 39-43
4. radjasandirane2023structuralanddynamic pages 1-2
5. kramer2024antibodytargetingof pages 1-2
6. faiz2023investigatingtherole pages 40-44
7. han2016calreticulinmutantproteinsinduce pages 1-2
8. beltranvisiedo2024cytofluorometricassessmentof pages 1-4
9. faiz2023investigatingtherole pages 30-34
10. varricchio2017calreticulinchallengesposed pages 9-11
11. migliaccio2018dissectingphysicalstructure pages 1-3
12. https://clinicaltrials.gov/study/NCT05025488
13. https://clinicaltrials.gov/study/NCT06150157
14. https://doi.org/10.1111/jcmm.17839
15. https://doi.org/10.3390/biom13030509
16. https://doi.org/10.1111/jcmm.17896
17. https://doi.org/10.1111/imr.13301
18. https://doi.org/10.1016/bs.mcb.2024.05.009
19. https://doi.org/10.1111/imr.13271
20. https://doi.org/10.1111/jcmm.17839,
21. https://doi.org/10.1158/2643-3230.bcd-21-0144,
22. https://doi.org/10.3389/fcell.2017.00096,
23. https://doi.org/10.1080/07391102.2017.1330224,
24. https://doi.org/10.1016/bs.mcb.2024.05.009,
25. https://doi.org/10.1111/imr.13301,
26. https://doi.org/10.3390/biom13030509,
27. https://doi.org/10.1111/jcmm.17896,
28. https://doi.org/10.1186/s13045-016-0275-0,